Bildkälla: Stockfoto

Alligator Bioscience: Update on ATOR-1017 - Redeye

Redeye views the update from the Phase I trial with ATOR-1017 in solid tumor patients as encouraging and in line with our expectations.

Redeye views the update from the Phase I trial with ATOR-1017 in solid tumor patients as encouraging and in line with our expectations.
Börsvärldens nyhetsbrev
ANNONSER